Table 2. Typology of general practitioners according to their practices and opinions about vaccination, agglomerative hierarchical cluster analysis, weighted data, France, April to July 2014 (n = 1,575).
| Vaccine hesitancy (%) | ||||
|---|---|---|---|---|
| No-to-slight n = 1,353 (85.9%) |
Moderate n = 166 (10.6%) |
High n = 56 (3.5%) |
All | |
| Perceived likelihood of links between specific vaccines and potential severe adverse effects (somewhat/very likely) | ||||
| Seasonal influenza vaccine and Guillain–Barré syndrome | 20.1 | 29.9 | 66.2 | 22.8 |
| Hepatitis B vaccine and multiple sclerosis | 5.8 | 30.3 | 82.8 | 11.1 |
| Aluminium adjuvants and Alzheimer's disease | 5.8 | 15.2 | 70.9 | 9.1 |
| AS03-adjuvanted influenza A(H1N1)pdm09 vaccine Pandemrix and narcolepsy | 13.9 | 28.8 | 46.4 | 16.6 |
| Human papilloma virus vaccine and multiple sclerosis | 0.2 | 27.4 | 50.5 | 4.8 |
| Vaccines containing adjuvant and long-term complications | 24.3 | 48.2 | 88.5 | 29.1 |
| Perceptions of vaccine usefulness (somewhat/strongly agrees) | ||||
| Today some vaccines recommended by authorities are not useful | 23.1 | 40.1 | 60.4 | 26.3 |
| Children are vaccinated against too many diseases | 16.4 | 36.5 | 62.4 | 20.1 |
| Frequency of vaccine recommendations (often/always) | ||||
| Measles-mumps-rubella (MMR) to non-immune adolescents and young adults | 87.1 | 55.8 | 52.6 | 82.6 |
| Meningococcal meningitis C to 12-month-old infants | 70.9 | 52.8 | 30.6 | 67.6 |
| Meningococcal meningitis C to ages 2–24 years (catch-up) | 60.6 | 36.2 | 20.8 | 56.6 |
| Human papillomavirus vaccine to girls aged 11–14 years | 77.5 | 46.9 | 24.5 | 72.4 |
| Hepatitis B to adolescents (catch-up) | 67.1 | 41.5 | 29.7 | 63.1 |
| Seasonal influenza to adults under 65 years with diabetes | 87.1 | 69.9 | 47.5 | 83.9 |
a Seven missing values.